LSK Global selects Veeva’s clinical applications to simplify trial processes

8th March 2021 (Last Updated March 8th, 2021 18:06)

Korean contract research organisation LSK Global Pharma Services has adopted three Veeva vault clinical applications to streamline the global trial processes.

LSK Global selects Veeva’s clinical applications to simplify trial processes
LSK Global selects Veeva’s clinical applications to simplify global trial processes. Credit: CDC on Unsplash.

Korean contract research organisation LSK Global Pharma Services has adopted three Veeva vault clinical applications to streamline the global trial processes.

LSK Global will use Veeva Vault eTMF, Veeva Vault CTMS, and Veeva SiteVault Free applications to streamline the trial process and remotely collaborate with study sponsors to review and verify the documents.

LSK Global Pharma Services president Young-Jack Lee said: “As a leading CRO, our aim is to run faster, more efficient trials.

“Veeva Vault Clinical applications enable us to operate remote trials, provides full visibility into end-to-end trial activities, and improves our collaboration with sponsors.”

Vault eTMF and Vault CTMS are part of Veeva vault clinical suite, which is claimed to be the industry’s first cloud platform that unifies clinical data management as well as the operations.

Vault eTMF (electronic trial master file) is said to be the only software that manages documents in real-time.

It ensures a constant state of inspection readiness by managing all TMF documents and processes in the same eTMF system.

The Veeva Vault CTMS improves operational efficiency, streamlines collaboration, and enables quick, high-quality trial execution.

Meanwhile, SiteVault Free, a free eRegulatory solution for clinical research sites, replaces the paper-based process and simplifies research by providing a modern Cloud application to manage investigator site files.

All the three applications together will allow LSK Global to fast-track the trial execution process and deliver real-time visibility within a short span of time.

Established in 2000, the company provides therapeutic area-specific services across oncology, cardiovascular disease and endocrinology.

As of December last year, it has conducted 1,277 clinical studies, including 144 global clinical studies and 110 IND studies.